Key Highlights

  • 4DMedical (ASX:4DX) fell about 3.8% intraday on 21 July 2026.
  • No confirmed company-specific announcement explained the decline.
  • The company continues expanding its XV lung imaging platform.
  • A proposed US veterans' healthcare bill remains under consideration.

Shares of 4DMedical Limited (ASX:4DX) eased about 3.8% during intraday trading on 21 July 2026 following a period of significant share price gains. No fresh company-specific announcement was identified to explain the move, with the decline appearing to reflect broader market activity after the stock's strong rally. The reported movement was an intraday reading rather than a closing price.

Lung Imaging Technology Drives the Business

4DMedical develops proprietary XV Technology, which produces four-dimensional functional lung imaging using existing medical imaging equipment. The platform is designed to help clinicians assess lung function and is marketed across healthcare providers in Australia and the United States through a software-as-a-service model. The company continues expanding its commercial footprint as adoption of its imaging technology grows.

Recent Performance and Commercial Progress

For the first half of FY2026, 4DMedical reported revenue of approximately AUD 2.85 million, while scan volumes more than doubled to over 151,900. SaaS sites increased to around 430 globally, reflecting continued commercial expansion. Following a capital raising completed in January 2026, the company also reported a strengthened cash position to support ongoing commercialisation efforts. A bipartisan US proposal, the AIRCARE for Vets Act, has also kept the company in focus, although it remains at the legislative stage.

What Investors May Watch Next

Investors may monitor progress of the proposed US veterans' healthcare legislation, growth in scan volumes, expansion of SaaS sites, future financial updates and additional commercial agreements. Continued adoption of XV Technology across healthcare providers may also remain an important development.

Risks

4DMedical remains exposed to commercialisation, regulatory, funding and technology adoption risks. Revenue growth depends on broader clinical adoption, while legislative developments, healthcare procurement timelines and continued operating losses could affect future performance.